LENALIDOMIDE PHARMACOKINETICS IN COMBINATION WITH IDARUBION AND CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.

被引：0
|
作者：
Jiang, Y. [1 ]
Wang, J. [2 ]
Walker, A. [3 ]
Li, X. [4 ]
Drake, A. [2 ]
Schaaf, L. [2 ]
Byrd, J. [3 ]
Marcucci, G. [3 ]
Grever, M. [3 ]
Blum, W. [3 ]
Phelps, M. [1 ]
机构：
[1] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [1] A new combination therapy with topotecan, cytarabine and mitoxantrone in patients with refractory or relapsed acute myeloid leukemia or blast crisis of chronic myeloid leukemia.
    Höchsmann, B
    Griesshammer, M
    Bergmann, L
    BLOOD, 1999, 94 (10) : 230B - 230B
  • [2] Phase I dose escalating trial of bortezomib (Veleade®) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia.
    Attar, EC
    DeAngelo, DJ
    Ballen, KK
    Learner, E
    Trehu, EG
    Schenkein, DP
    Levine, JD
    Stone, RM
    Amrein, PC
    BLOOD, 2004, 104 (11) : 498A - 499A
  • [3] Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
    Ferrara, F
    Mele, G
    Califano, C
    Palmieri, S
    Pocali, B
    Denise, P
    Copia, C
    D'Arco, AM
    BLOOD, 2002, 100 (11) : 344A - 344A
  • [4] Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.
    Smith, Catherine Choy
    Levis, Mark J.
    Litzow, Mark Robert
    Perl, Alexander E.
    Altman, Jessica K.
    Gill, Stan
    Yuen, Geoffrey
    Bonate, Peter
    Kadokura, Takeshi
    James, Angela Joubert
    Liu, Charles
    Nagase, Itsuro
    Fisniku, Ogert
    Bahceci, Erkut
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [6] Combination of datmorubicin and cytarabine chemotherapy with gemtuzumab ozogamicin as initial therapy for elderly patients with previously untreated acute myeloid leukemia.
    Kujawski, LA
    Ryan, I
    Griffith, K
    Erba, HP
    BLOOD, 2005, 106 (11) : 238B - 238B
  • [7] Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia.
    DeAngelo, D
    Russo, D
    Castaigne, S
    Esteve, J
    Burnett, A
    Goldstone, A
    Tallman, M
    Bradstock, K
    Lowenberg, B
    Leopold, L
    Munteanu, M
    Eten, C
    Berger, M
    BLOOD, 2001, 98 (11) : 199B - 199B
  • [8] Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
    Lin, Tara L.
    Wood, Robyn
    Ham, Tammy
    Sullivan, Taegen
    Bhattacharyya, Sangita
    Dandawate, Prasad
    Anant, Shrikant
    Santaguida, Marianne T.
    Zhang, Na
    Toren, Paul
    Jensen, Roy A.
    Taylor, John A.
    Baltezor, Michael Jay
    Dalton, Michael
    McBride, John
    Umbreit, Jay Nicholas
    McCulloch, William
    Vanderlaag, Kathryn
    Wagner, Joseph
    Weir, Scott James
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
  • [10] Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.
    Myers, Kasian C.
    Gerbing, Robert B.
    Alonzo, Todd A.
    Phillips, Christine L.
    Gamis, Alan S.
    Radloff, Gretchen A.
    Perentesis, John
    Davies, Stella M.
    BLOOD, 2009, 114 (22) : 1024 - 1024
12345